COST EFFECTIVENESS OF VENTRICULAR TACHYCARDIA ABLATION VERSUS ESCALATION OF ANTIARRHYTHMIC DRUG THERAPY IN THE VANISH TRIAL

摘要

BACKGROUND: For survivors of myocardial infarction with implantable cardioverter-defibrillator (ICD) shocks despite antiarrhythmic drugs, the VANISH trial demonstrated improved clinical outcomes with catheter ablation compared to additional pharmacotherapy. This analysis uses the data from the randomised controlled trial to assess the cost effectiveness of catheter ablation (n= 132) versus escalated antiarrhythmic therapy (escalated drug therapy) (n=127).